Holen Sie sich die Stockscreener-App
202.08
0.60%
1.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$200.88
Offen:
$200.32
24-Stunden-Volumen:
4.96M
Relative Volume:
0.91
Marktkapitalisierung:
$356.74B
Einnahmen:
$56.33B
Nettoeinkommen (Verlust:
$4.28B
KGV:
84.20
EPS:
2.4
Netto-Cashflow:
$17.83B
1W Leistung:
+4.78%
1M Leistung:
+17.07%
6M Leistung:
+2.82%
1J Leistung:
+15.38%
1-Tages-Spanne:
$200.01
$203.97
1-Wochen-Bereich:
$190.67
$203.97
52-Wochen-Spanne:
$153.58
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance
Parenteral Nutrition Market Future Business Opportunities - openPR
AbbVie Inc. (ABBV) Stock: Pharmaceutical Sector Investment Option - INDODAX
Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020–2034) as New Innovations Drive Therapy Advancements | DelveInsight - GlobeNewswire Inc.
AbbVie Inc. (ABBV) Announces $4 Billion Senior Notes Offering - GuruFocus.com
Real-World Evidence in IBD: Driving Innovative Approaches to Care - AbbVie
AbbVie Appears Ready To Move Higher - Seeking Alpha
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Is AbbVie Stock a Buy Now? - MSN
ABBV Quantitative Stock Analysis - Nasdaq
Beyond the Possible: How AbbVie Uses Technology to Transform Medicines for Patients - CBS News
How Is The Market Feeling About AbbVie? - Benzinga
ABBV: 3 Dividend Growth Stocks for Long-Term Wealth - StockNews.com
Aseptic Fill Finish Market Top Companies StudyAenova, AbbVie - openPR
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now - Insider Monkey
10 Best Drug Stocks to Buy Now - Insider Monkey
AbbVie Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Focus Financial Network Inc. Trims Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Roxbury Financial LLC Invests $496,000 in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Rhumbline Advisers - MarketBeat
BXM Wealth LLC Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Autumn Glory Partners LLC Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Blue Trust Inc. Buys 8,959 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
WealthPLAN Partners LLC Lowers Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Adell Harriman & Carpenter Inc. Buys 2,721 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
New Mexico Educational Retirement Board Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie’s Next Chapter: A Beacon of Opportunity in Biopharma - Jomfruland.net
AbbVie Inc. (NYSE:ABBV) Shares Sold by Vontobel Holding Ltd. - MarketBeat
Compound Global Advisors LLC Invests $311,000 in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Robert Michael to succeed Gonzalez as Abbvie’s chair - BioCentury
Kentucky Trust Co Purchases Shares of 7,089 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Axecap Investments LLC Has $4.24 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) to Issue $1.64 Quarterly Dividend - MarketBeat
7th Circ. Says Ex-AbbVie Worker Filed Race Bias Suit Too Late - Law360
AbbVie (NYSE:ABBV) Trading Up 0.4%Still a Buy? - MarketBeat
AbbVie Inc. (ABBV) reports earnings - Quartz
AbbVie Inc. SEC 10-K Report - TradingView
AbbVie names CEO Robert Michael as board chair, Richard Gonzalez departs - MM+M Online
AbbVie's new CEO tapped for board chairman - Crain's Chicago Business
AbbVie: An Undervalued Dividend Aristocrat (NYSE:ABBV) - Seeking Alpha
Correction to AbbVie Names CEO Robert Michael Chairman Article -February 14, 2025 at 09:52 am EST - Marketscreener.com
AbbVie Lauds Michael as Chairman, CEO - Baystreet.ca
AbbVie: CEO to become Chairman of the Board -February 14, 2025 at 09:24 am EST - Marketscreener.com
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
AbbVie Just Paid Investors: Here's How Much They Received - 24/7 Wall St.
AbbVie Names CEO Robert Michael as Board Chairman -February 14, 2025 at 07:59 am EST - Marketscreener.com
AbbVie Appoints Robert A. Michael as Chairman - TipRanks
AbbVie names Robert Michael as chairman of board of directors - TipRanks
New York State Teachers Retirement System Has $283.57 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Chevy Chase Trust Holdings LLC Has $170.82 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):